BCL2L1 and hepatocellular carcinoma: Since a novel BH3-mimetic, A-1210477 [34], highly specific for MCL-1 has been recently described, we tested it, in order to deplete MCL-1 levels in hepatoma cells and combined with BCL-xL reduction using A-1331852.